Roche Appoints North American Head Matt Sause as Next CEO of Diagnostics Division
By LabMedica International staff writers Posted on 06 Oct 2022 |
Roche (Basel, Switzerland) has announced that Matt Sause, currently Head of Roche Diagnostics’ North America Region, will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
Matt began his career with Roche in the U.S. in 2002 as a Senior Molecular Account Manager and progressed in various commercial general management and global product leadership roles spanning both the Diagnostics and Pharma divisions in multiple countries such as Japan, Ireland, Peru, and South Korea. In 2018, he moved to Genentech in the United States to become Lifecycle Leader for Tecentriq Lung and Head and Neck Cancers before eventually taking over his current role as President and CEO for Roche Diagnostics North America. Matt holds a Bachelor’s degree in Microbiology from Miami University and an MBA from University of California, San Diego.
“Matt Sause’s career at Roche has spanned twenty years in multiple countries across Asia, Latin America, Europe and North America in both the Diagnostics and Pharma divisions. His combination of scientific knowledge with commercial experience makes him an excellent leader for the Diagnostics division,” said Thomas Schinecker, the incumbent CEO of the Diagnostics Division and new Roche CEO as of 15 March 2023.
"Matt Sause has had an exceptional career with Roche and I am very pleased that we can once again internally appoint a leader of his caliber to become the next CEO Roche Diagnostics," said Severin Schwan, currently Roche CEO, who has been proposed by the Roche Board of Directors as the new Chairman of Roche at the Annual General Meeting on 14 March 2023.
Related Links:
Roche
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus